Information Provided By:
Fly News Breaks for January 30, 2017
NBIX, PRTA, BMRN, EXEL
Jan 30, 2017 | 07:16 EDT
Deutsche Bank analyst Andrew Peters says that while pricing headwinds are likely to dominate the near-term conversation, there is a "lot to like" in 2017 in the Biotechnology space. Fundamentals, when focusing on the longer term, remain strong and present an opportunity, Peters tells investors in a research note. He lists Exelixis (EXEL), BioMarin (BMRN), Prothena (PRTA) and Neurocrine (NBIX) as among his favored stocks for 2017.